Transabdominal mesh complications and lawsuit settlements

Transabdominal mesh represents a surgical approach for treating pelvic organ prolapse (POP) that has maintained FDA approval and demonstrates a significantly better safety profile than transvaginal mesh procedures. For patients facing decisions about pelvic floor surgery, understanding the critical differences between these approaches is essential for informed consent and optimal outcomes.

This guide covers the safety profiles, surgical procedures, FDA regulatory actions, and legal landscape surrounding surgical mesh devices used to treat pelvic floor disorders. The information serves patients considering mesh surgery, individuals with existing implants seeking clarity about their options, and healthcare decision-makers evaluating treatment pathways.

Transabdominal mesh procedures, particularly laparoscopic sacrocolpopexy, remain FDA-approved and are widely considered the gold standard for apical prolapse repair, with mesh-related complication rates around 3% compared to approximately 10-18% for transvaginal mesh approaches. This distinction underlies the FDA’s 2019 decision to ban transvaginal POP mesh while permitting transabdominal placement to continue.

By reading this article, you will understand:

• Why transabdominal mesh has a superior safety profile compared to transvaginal approaches
• How the FDA ban specifically targeted transvaginal POP mesh while leaving other procedures unaffected
• Which surgical mesh manufacturers face ongoing litigation
• What non-mesh treatment alternatives exist for pelvic organ prolapse
• How to evaluate risks and benefits when considering pelvic surgery

Understanding Transabdominal Mesh

Surgical mesh technology has transformed the treatment of female pelvic floor disorders, offering reinforcement for weakened or damaged tissue that native tissue repairs alone may not provide. The majority of surgical mesh devices currently available are made from synthetic materials or animal tissue. Mesh is commonly used for repairing weakened tissues, providing additional support where the body’s own tissues are insufficient. Understanding how transabdominal mesh functions helps patients make informed decisions about their surgical management options.

What is transabdominal mesh?

Transabdominal mesh is a minimally invasive surgical treatment that involves introducing mesh to support pelvic organs via a tiny incision in the abdomen or laparoscopically. This approach differs fundamentally from transvaginal mesh surgery, where synthetic material is placed through an incision in the vaginal wall.

The abdominal approach positions mesh away from the vaginal epithelium, which significantly reduces the risk of mesh exposure and erosion into the vagina—complications that plagued transvaginal mesh procedures. Most surgical mesh used in transabdominal placement consists of lightweight, large-pore monofilament polypropylene, a synthetic mesh material designed for tissue integration while minimizing inflammatory response.

In sacrocolpopexy procedures, surgeons access the pelvis through small incisions in the abdomen, attach mesh strips to the anterior and posterior vaginal wall from above, and anchor the mesh to the sacral promontory (the bony prominence at the base of the spine). The peritoneum is then closed over the implanted mesh to reduce bowel adhesion risk.

How Transabdominal Mesh Works

The mechanism of transabdominal mesh involves creating a supportive bridge between prolapsed pelvic organs and stable skeletal structures. When treating pelvic organ prolapse, the mesh acts as a bridging material that reinforces the weakened vaginal wall and restores anatomical support.

Over time, the body’s natural healing processes incorporate the mesh into surrounding tissues. Collagen fibers grow through the mesh pores, creating a durable scaffold that maintains organ position. This integration is why transabdominal placement has demonstrated long-term success rates exceeding 90% for apical prolapse repair in many studies.

The positioning of mesh above the vaginal tissue—rather than within or immediately beneath it—explains why transabdominal procedures experience lower rates of mesh erosion and mesh complications than transvaginal repair. This anatomical advantage has been studied over more than 30 years, establishing transabdominal sacrocolpopexy as the gold standard for apical pelvic organ prolapse POP repair.

Diagnostic Evaluation Before Mesh Procedures

Before proceeding with any surgical procedure involving mesh to treat pelvic organ prolapse, stress urinary incontinence, or other pelvic floor disorders, a comprehensive diagnostic evaluation is essential. This critical step ensures that both patients and health care providers have a clear understanding of the underlying condition, the extent of weakened or damaged tissue, and the most appropriate treatment options—including whether surgical mesh is indicated.

The diagnostic process typically begins with a detailed medical history, where patients are asked about their symptoms, previous pelvic floor surgery, history of urinary incontinence, and any prior treatments for prolapse or pelvic pain. This conversation helps identify risk factors for mesh complications and guides the selection of the most suitable surgical procedure.

A thorough physical examination follows, focusing on the pelvic floor to assess for signs of prolapse, weakened vaginal wall, or other pelvic floor disorders. During this exam, health care providers evaluate the degree of organ descent, the integrity of supporting tissues, and any evidence of mesh exposure or erosion if prior mesh has been implanted.

Imaging studies, such as pelvic ultrasound or MRI, may be recommended to visualize the bladder, uterus, and surrounding structures. These tests can help clarify the severity of prolapse, detect mesh-related complications like mesh erosion, and inform surgical planning. In some cases, imaging can also identify issues such as urinary tract infection or damage to adjacent organs that may influence the choice of surgical mesh devices or the need for alternative treatments.

For patients with urinary incontinence or complex pelvic floor symptoms, urodynamic studies are often performed. These specialized tests assess bladder function, measure urine flow, and help distinguish between stress urinary incontinence and other types of voiding dysfunction. The results are crucial for tailoring the surgical approach—such as deciding between a midurethral sling or other interventions—and for minimizing postoperative risks.

Throughout the diagnostic evaluation, health care providers should engage in open discussions with patients about the risks and benefits of mesh procedures. This includes reviewing the types of mesh available, such as synthetic mesh or animal tissue grafts, and explaining the potential for mesh complications like mesh exposure, persistent vaginal bleeding, or the rare need for repeat surgery. Patients should be informed about the FDA’s regulatory status of various surgical mesh devices, including the distinction between transvaginal mesh and transabdominal mesh for pelvic organ prolapse repair.

The American Urogynecologic Society and other professional organizations emphasize that a thorough diagnostic evaluation is the foundation of safe and effective pelvic floor surgery. By carefully assessing each patient’s unique anatomy, medical history, and treatment goals, health care providers can develop a personalized surgical management plan that maximizes benefits and minimizes risks.

Ultimately, a comprehensive diagnostic evaluation empowers patients to make informed decisions about their care, whether they choose surgical mesh, native tissue repair, or conservative management. It also helps ensure that any potential complications are identified early, allowing for prompt treatment and improved outcomes in the management of pelvic floor disorders.

Transabdominal Mesh Procedures and Applications

The clinical applications of transabdominal mesh span several pelvic floor disorders, with specific medical procedures designed for different conditions. Transabdominal mesh is commonly used in a variety of medical procedures, including surgeries for pelvic organ prolapse and stress urinary incontinence. Understanding these surgical procedures helps patients engage meaningfully with health care providers about their treatment options.

What is the mid-urethral sling procedure?

The midurethral sling procedure is the most commonly performed surgical treatment for female stress urinary incontinence, using a narrow strip of synthetic mesh to support the urethra during activities that increase abdominal pressure.

Step 1: The surgeon makes three small incisions (one in the vagina, two above the pubic bone).

Step 2: A thin strip of synthetic mesh is inserted under the urethra.

Step 3: The mesh is used to raise and support the urethra and bladder neck.

This mesh sling creates a supportive hammock that prevents urinary leakage during coughing, sneezing, or physical exertion. The midurethral sling procedure has success rates of 70-90% over 5-10 years and remains endorsed by professional organizations including the American Urogynecologic Society as an effective treatment for stress incontinence.

In cases where sling release is necessary, a small incision is made at the previous incision site or the anterior vaginal sulcus to access and transect the sling.

Two primary approaches exist for mid-urethral slings: the retropubic technique (passing behind the pubic bone) and the transobturator technique (passing through the obturator foramen near the inner thigh). Both have demonstrated comparable long-term outcomes, though they differ in their specific risk profiles for complications like voiding dysfunction and pelvic pain.

Laparoscopic Sacrocolpopexy

Laparoscopic and robotic-assisted laparoscopic sacrocolpopexy represent the gold standard for treating vaginal vault prolapse and recurrent prolapse. This surgical repair addresses apical prolapse—descent of the top of the vagina—which can occur after hysterectomy or as part of uterine prolapse.

During the procedure, surgeons make small port incisions around the umbilicus and lower abdomen. Using camera guidance and specialized instruments, they dissect to expose the vaginal walls from above, suture mesh strips to these tissues, and anchor the mesh to the anterior longitudinal ligament over the sacrum. The peritoneum is closed over the mesh to protect against bowel adhesions.

Compared to native tissue repairs, laparoscopic sacrocolpopexy demonstrates superior anatomic outcomes with lower prolapse recurrence rates. The Mayo Clinic notes that abdominal approaches allow for better visualization and more secure mesh attachment, contributing to better long-term results for complex prolapse cases.

Minimally Invasive Surgical Applications

How is transabdominal mesh used in minimally invasive surgeries? Modern transabdominal placement techniques minimize surgical trauma while achieving excellent outcomes for several conditions.

Laparoscopic approaches use carbon dioxide insufflation to create working space, with small incisions typically measuring 5-12mm. Patients experience less postoperative pain, shorter hospital stays, and faster return to normal activities compared to open surgery.

Robotic-assisted surgery adds enhanced precision through wristed instruments and magnified three-dimensional visualization. While outcomes are comparable to standard laparoscopy, some surgeons prefer robotic assistance for complex reconstructive surgery requiring intricate dissection and suturing.

Sacrohysteropexy offers women desiring uterine preservation an alternative to hysterectomy. Mesh is anchored to the cervix or uterus rather than the vaginal vault, maintaining support while preserving the organ.

The advantages of minimally invasive transabdominal placement include reduced blood loss, decreased infection risk, and similar or superior long-term anatomic success compared to both open abdominal procedures and vaginal approaches.

Safety Profile and Regulatory Status

Understanding the regulatory history and safety data surrounding surgical mesh devices helps patients appreciate why transabdominal mesh remains an accepted treatment while transvaginal mesh for POP has been removed from the market. The FDA requires manufacturers to provide reasonable assurance of safety and effectiveness for surgical mesh devices before approval.

After the FDA ban on transvaginal mesh for POP and the regulatory distinctions between different types of mesh, the FDA’s ruling has caused confusion among women regarding the safety and effectiveness of all pelvic floor surgeries that use mesh.

FDA Status of Transabdominal Mesh

The U.S. Food and Drug Administration maintains clear distinctions between different pelvic mesh applications. Transabdominal mesh for pelvic organ prolapse remains FDA-approved, as does synthetic mesh for mid-urethral slings treating stress urinary incontinence.

The FDA ban on surgical mesh devices for pelvic floor disorders applies specifically to transvaginal mesh products for POP repair—not to abdominal mesh procedures or stress incontinence slings. This distinction reflects the significantly different safety profiles between approaches.

Key regulatory timeline:

• 1996: FDA clearance of first synthetic mesh for SUI mid-urethral slings
• 2002: FDA clearance of first transvaginal mesh for POP repair
• 2008: FDA Public Health Notification warning of complications
• 2011: FDA Safety Communication stating transvaginal POP mesh complications “are not rare”
• 2016: FDA reclassifies transvaginal POP mesh to Class III (high risk), requiring premarket approval
• April 2019: FDA orders remaining manufacturers to stop selling transvaginal POP mesh

Why did the FDA ban specific surgical mesh products? The agency concluded that manufacturers’ premarket approval applications failed to demonstrate that benefits outweighed risks compared to native tissue repairs. High rates of mesh exposure, pelvic pain, dyspareunia, and repeat surgery—combined with lack of superior patient-reported outcomes—led to the determination that transvaginal POP mesh should not remain on the market.

Safety Comparison: Transabdominal vs Transvaginal Mesh

Is transabdominal mesh safer than vaginal mesh? For pelvic organ prolapse repair, evidence strongly supports the superior safety of the transabdominal approach. How do transvaginal and transabdominal mesh procedures differ in safety?

The fundamental difference lies in mesh positioning. Transvaginal placement requires incisions through the vaginal wall, creating direct contact between mesh and vaginal epithelium. This proximity increases mesh erosion risk, where the implanted mesh protrudes through the vaginal tissue, causing persistent vaginal bleeding, vaginal discharge, pain, and often requiring additional surgery. An exposed piece of mesh may protrude through the vaginal wall, leading to symptoms such as discomfort, discharge, or partner issues, and may require additional intervention. Mesh exposure or erosion can also cause symptoms such as spotting, discharge, or partner discomfort during sex. Pain during sex, known as dyspareunia, can be a complication related to mesh placement. You should notify your health care provider if you have complications or symptoms, including persistent vaginal bleeding or discharge, pelvic or groin pain, or pain with sex.

How do abdominal and transvaginal mesh surgeries differ in safety? Transabdominal placement keeps mesh separated from vaginal tissue by positioning it in the abdomen and anchoring to stable skeletal structures. This anatomical advantage explains the approximately six-fold reduction in mesh exposure rates.

However, transabdominal mesh is not risk-free. Potential complications include general surgical risks (bleeding, infection, injury to bladder or bowel), rare but serious conditions like sacral osteomyelitis, and typical mesh-related risks including chronic pelvic pain and the rare need for mesh removal.

What is vaginal prolapse?

Vaginal prolapse is a condition that occurs when the vaginal vault (the upper part of the vagina) collapses and protrudes into the vaginal canal. This pelvic floor disorder affects approximately 3-6% of women and is more common after childbirth, menopause, hysterectomy, and in conditions affecting connective tissue.

Types of pelvic organ prolapse include:

• Cystocele: Bladder descent into the anterior vaginal wall
• Rectocele: Rectal bulging into the posterior vaginal wall
• Uterine prolapse: Descent of the uterus into the vaginal canal
• Enterocele: Small bowel herniation into the upper vagina
• Vaginal vault prolapse: Descent of the vaginal apex after hysterectomy

Risk factors include multiple vaginal deliveries, aging, obesity, chronic constipation or cough, heavy lifting, and connective tissue disorders. Symptoms range from a sensation of vaginal bulging to urinary incontinence, fecal incontinence, and difficulties with bowel movements.

Understanding prolapse types helps patients and their health care providers determine appropriate treatment approaches—from conservative management with pessaries to surgical repair with or without mesh reinforcement.

Vaginal Prolapse: “When the vaginal vault (the upper part of the vagina) collapses and protrudes into the vaginal canal, this condition is known as vaginal prolapse”. 

Postpartum Prolapse: “Pelvic organ prolapse after childbirth occurs when weakened pelvic floor muscles and tissues allow organs like the bladder, uterus, or rectum to drop from their normal position into the vaginal…”. 

Transabdominal Mesh: “Transabdominal mesh to treat pelvic organ prolapse : This minimally invasive surgery involves introducing the mesh to support organs via a tiny incision in the abdomen or laparoscopically (small incisions around the pelvic muscles navel and using a camera)”.

Mid-Urethral Sling: “Procedure for using a mid-urethral sling : This is the most often utilized procedure to treat stress urinary incontinence. Your surgeon will make three smaller incisions (one in your vagina and two above your pubic bone) and inserts a thin strip of synthetic mesh under your urethra to raise and support it and the bladder neck”.

The FDA Ban: “Manufacturers of most surgical mesh used to treat pelvic floor disorders (Boston Scientific Uphold Lite, Boston Scientific Xenform, Coloplast Direct Fix Anterior) were told by the FDA on April 16, 2019, that they must immediately cease sales and distribution of their products while the agency reviews their premarket approval (PMA) applications”. 

Device Reclassification: “Pelvic mesh for pelvic organ prolapse was reclassified by the FDA in 2016 from class II (low risk) to class III (high risk)…”.

Recovery Time: “The typical recovery time for bladder mesh removal is four to six weeks. During this period, vaginal incisions heal, sutures dissolve, and most women can return to routine activities…”.

Safety Alternative: “While the surgery has been linked to significant and often disabling consequences for thousands of women, abdominal mesh surgery is generally considered a safer alternative”.

Manufacturers and Brands: “The following are the most common surgical mesh manufacturers and products:

• Boston Scientific – Advantage, Advantage Fit, Obtryx, Lynx Pinnacle, Prefyx, Uphold American Solyx
• Medical Systems – Elevate, Apogee, BioArc, Monarc, IN-Fast, MiniArc, Perigee, Sparc
• Coloplast Corp. – Restorelle Smartmesh, Novasilk Synthetic Flat Mesh, Exair Mesh…
• C.R. Bard, Inc. Pelvisoft, Pelvicol, Pelvilace…

Surgical Mesh Materials and Complication Management

Surgical mesh made of synthetic materials can be found in knitted mesh or non-knitted sheet forms. Non-absorbable materials in surgical mesh will remain in the body permanently and are used to provide permanent reinforcement. Animal-derived mesh is made from processed and disinfected animal tissue, such as intestine or skin. The majority of animal-derived mesh used in surgical procedures is sourced from pigs (porcine) or cows (bovine). In conclusion, surgical mesh is available in various synthetic and animal-derived forms designed for permanent or biological reinforcement.

A careful history and physical examination is essential in the diagnosis of mesh and graft complications. Approaches to management of mesh-related complications in pelvic floor surgery include observation, physical therapy, medications, and surgery. If you have mesh-related problems after your surgery, you may need another surgery to remove the mesh. Women who are not symptomatic have no role for intervention regarding mesh removal. In conclusion, the management of mesh complications requires a thorough diagnosis and ranges from conservative observation to surgical removal depending on the symptoms present.

Legal Landscape and Manufacturer Accountability

The legal ramifications of mesh complications have resulted in some of the largest medical device litigation in U.S. history, with billions of dollars in settlements paid to patients who experienced adverse events.

Which surgical mesh manufacturers are facing lawsuits?

• Ethicon (Johnson & Johnson)
• Coloplast
• Boston Scientific

Additional manufacturers involved in pelvic mesh litigation include C.R. Bard (now part of BD), American Medical Systems (AMS)/Endo International, Cook Medical, and various smaller companies. Tens of thousands of lawsuits were consolidated into multidistrict litigations (MDLs) in federal courts, creating some of the most complex mass tort proceedings in legal history.

The litigation has centered primarily on transvaginal POP mesh kits, though some cases involve mid-urethral slings and, to a lesser extent, abdominally placed mesh. Patients experiencing mesh-related complications should consult with attorneys specializing in medical device litigation to understand their potential eligibility for compensation.

Common Legal Grounds for Mesh Lawsuits

What are the common legal grounds for mesh injury lawsuits? Plaintiffs have pursued several legal theories against mesh manufacturers:

Failure to warn: Allegations that manufacturers failed to adequately disclose risks including chronic pain, mesh erosion, dyspareunia, and the potential need for multiple surgical procedures. Plaintiffs argue that proper warnings would have allowed patients and surgeons to make fully informed decisions.

Defective design: Claims that mesh materials (particularly heavyweight polypropylene with small pore sizes) and transvaginal kit designs were inherently prone to complications including contraction, erosion, and tissue damage.

Defective manufacturing: Allegations that specific product lots contained substandard materials or manufacturing defects contributing to complications.

Negligent marketing: Claims that manufacturers aggressively promoted mesh kits as superior to native tissue repairs despite limited long-term safety data, and trained surgeons to perform procedures without adequate emphasis on risks.

Inadequate testing: Arguments that the FDA’s 510(k) pathway allowed devices to reach market with minimal clinical evidence, and that proper premarket approval studies would have revealed unacceptable risk levels.

Settlement Information and Patient Rights

Major mesh manufacturers have paid billions of dollars to settle claims, with individual settlements varying based on injury severity, medical expenses, and case-specific factors. Settlement eligibility typically requires documented mesh implantation and evidence of complications such as mesh exposure, chronic pain, or need for revision surgery.

Patients with transabdominal mesh complications and lawsuit settlements represent a smaller subset of mesh litigation than transvaginal cases, but some have successfully obtained compensation. The legal process typically involves medical record review, expert evaluation, and either settlement negotiation or trial.

For patients experiencing symptoms potentially related to implanted mesh—including new or worsening pelvic pain, urinary tract infection, vaginal scarring, or signs of mesh exposure—prompt treatment and documentation are essential both for health and for preserving legal options.

Treatment Alternatives and Decision Making

Understanding the full range of treatment options empowers patients to make informed decisions aligned with their values, health status, and risk tolerance.

Non-Mesh Treatments for Pelvic Floor Disorders

What non-mesh treatments are available for pelvic organ prolapse? Several effective options exist that avoid synthetic material entirely:

Conservative management:

• Pelvic floor physical therapy: Supervised exercises can strengthen supporting muscles and improve mild to moderate prolapse symptoms
• Pessary devices: Silicone support devices inserted in the vagina can mechanically hold organs in position, offering a non-surgical solution for patients who are poor surgical candidates or prefer to avoid surgery
• Lifestyle modifications: Weight loss, treating chronic constipation, and avoiding heavy lifting can reduce prolapse progression

Surgical options without mesh:

• Native tissue vaginal repairs: Anterior and posterior colporrhaphy for cystocele and rectocele, using the patient’s own tissue rather than synthetic reinforcement
• Uterosacral or sacrospinous ligament fixation: Procedures that anchor the vaginal apex to strong pelvic ligaments without mesh
• Hysterectomy with native tissue suspension: Removal of prolapsed uterus with vault support using natural ligaments

For stress urinary incontinence, what are the gold standard treatments? While mid-urethral slings represent the surgical gold standard, alternatives include:

• Autologous fascial slings: Using the patient’s own tissue (typically from the thigh or abdomen) instead of synthetic mesh
• Burch colposuspension: An abdominal procedure that elevates the bladder neck without mesh
• Urethral bulking agents: Injectable materials that narrow the urethra, though with lower durability than surgical options

The American College of Obstetricians and Gynecologists provides practice bulletin guidance on evaluating surgical options, emphasizing individualized decision-making based on prolapse severity, patient preferences, and surgeon expertise.

Questions to Ask Your Healthcare Provider

Before proceeding with any pelvic floor surgery, patients should discuss:

About necessity:

• Is mesh necessary for my specific condition, or would native tissue repair be effective?
• What are my realistic expectations for symptom improvement with each approach?
• What is the likely outcome if I choose conservative management instead?

About risks and benefits:

• What are the specific complications I might experience with the recommended procedure?
• What are the rates of mesh exposure, chronic pain, and need for revision with your technique?
• How does my health status affect my risk profile?

About surgeon qualifications:

• How many of these procedures have you performed?
• What specialized training in female pelvic medicine and reconstructive surgery do you have?
• Are you comfortable managing mesh complications if they occur?

About postoperative expectations:

• What symptoms should prompt me to seek immediate care?
• What long-term follow-up is recommended?
• What limitations should I expect during recovery?

Patients may consider seeking evaluation from a urogynecologist—a specialist in female pelvic medicine and reconstructive surgery—particularly for complex cases, recurrent prolapse, or when considering mesh procedures.

Conclusion and Next Steps

Transabdominal mesh procedures maintain an important role in treating pelvic organ prolapse, with safety profiles substantially superior to the now-banned transvaginal mesh approaches. The approximately 3% mesh-related complication rate for abdominal sacrocolpopexy compares favorably to rates exceeding 10% for transvaginal POP mesh, explaining both regulatory and clinical consensus favoring the abdominal approach when mesh is indicated.

Immediate action steps for patients:

1. Schedule consultation with a board-certified urogynecologist for comprehensive evaluation
2. Request detailed discussion of mesh and non-mesh options specific to your condition
3. If experiencing potential mesh complications, seek prompt treatment and document symptoms
4. Consider second opinions for complex cases or when uncertain about recommendations
5. Research surgeon experience and outcomes for recommended procedures

For patients with existing mesh who are experiencing complications, evaluation by a surgeon experienced in mesh removal is essential. Mesh-related complications including exposure, chronic pain, and voiding dysfunction may be manageable, but early intervention generally improves outcomes.

Additional Resources

The following resources provide authoritative information for patients researching surgical mesh options:

• FDA Urogynecologic Surgical Mesh Information – Official regulatory guidance and safety communications
• FDA Surgical Mesh for Hernia Repair – Background on mesh materials and general considerations
• Mayo Clinic: Vaginal Mesh Surgery – Patient-oriented explanation of procedures and risks
• Yale Medicine: Transvaginal Mesh Information – Clear distinctions between mesh approaches
• HSE Vaginal Mesh Implants Overview – International perspective on mesh applications
• ACOG Mesh Complications Management – Clinical guidance for healthcare providers
• PMC Review: To Mesh or Not to Mesh – Peer-reviewed analysis of pelvic reconstructive surgery evidence

Professional organizations including the American Urogynecologic Society and American College of Obstetricians and Gynecologists publish updated guidance that health care providers use in clinical decision-making. Patients can access patient education materials through these organizations to supplement discussions with their surgeons.